Close 10 Sep 1505 scanned A
NIFTY 5023,477.80+0.20%
BANK NIFTY56,471.95+0.31%
INDIA VIX11.80-1.05%
MIDCAP 15022,904.25-0.38%
SMALLCAP 25018,433.40+0.01%
NEXT 5072,530.90-0.44%
BREADTH61%above 200-DMA
ADV / DEC558 / 939
NSE close 10 Sep

JLHL

Jupiter Life Line Hospital
HealthcareSmall capRs 1,842 crRs 3.0 cr traded a day
Close on 10 September 2026
281.00
−0.35%
52-week range44% of the way up
239.98332.40
Market cap
1,842 cr
P/E (TTM)
9.9×
industry 45×
EPS (TTM)
28.39
Revenue YoY
+43.1%
Q1 FY27
Profit YoY
-15.9%
Net margin
9.1%
-6.4pt vs a year ago
Growth trend
+25.5pt
vs last quarter’s YoY
1 month
-8.2%
Below 52w high
18.3%
RSI (14)
22
oversold
Daily swing
3.7%
average true range
Volume
0.2×
vs 20-day average
Traded
Rs 3 cr
median day
Close200-day averageMaterial filing
250300Sep 25Nov 25Jan 26Mar 26May 26Jul 26Sep 26
260 sessions · hover for the filing behind a move

Key metrics

each ranked against every stock scanned tonight
Above the 200-day average
Around the median
+2.9%
One-year return
Around the median
-4.9%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+43.1%
Below the 52-week high
from the highest close of the year
-15.5%
1 week
−3.20%
1 month
−8.24%
3 months
+5.96%
6 months
+9.59%
1 year
−4.94%

The read

written from the numbers on this page
The evidence leans constructive6 supporting, 3 against, 2 worth knowing

Supporting

  • trading 3% above its 200-day average
  • matches growing fast, sold off anyway, which has beaten the market by +1.11 points over 20 sessions across 29,180 past signals
  • 3 of the scans it matches have a positive measured record
  • 4 independent kinds of evidence agree today, which is uncommon
  • revenue grew 43% year on year in the quarter ending 30 June 2026
  • priced at 10× earnings against an industry median of 45× — 78% below its peers

Against

  • down 5% over twelve months
  • 1 of the scans it matches has historically underperformed the market
  • net margin has narrowed from 15.5% to 9.1% across four quarters

Worth knowing

  • the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
  • RSI at 22 is washed out — historically the better half of this site's measured edge comes from exactly this condition
What would change this read: a close below 273, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

What is working, what is not

from the filings and from the price, with the figure behind every line
Working3

Revenue rose 41.5% year on year, from Rs 290 cr to Rs 411 cr.

+41.5%Rs 290 crRs 411 cr

Trading 2.9% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.

+2.9%

4 different kinds of evidence point at it tonight, not 4 versions of the same one.

4 families
Needs watching4

Profit grew slower than revenue, -17.1% against +41.5%.

-17.1%+41.5%

Net margin fell from 15.6% to 9.1%.

15.6%9.1%

Net profit -17.1% year on year, Rs 45 cr to Rs 38 cr.

-17.1%Rs 45 crRs 38 cr

Only Rs 3.0 crore changes hands on a median day. A large order moves this price by itself.

Rs 3.0 cr
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 2 of these 4 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.

How it has performed

price return over each window, beside the median NSE stock over the same days
this stockmedian NSE stock, same window-3.2%-2.4 pt vs market1W-8.2%-7.2 pt vs market1M+6.0%+3.3 pt vs market3M+9.6%-7.0 pt vs market6M-4.9%-1.8 pt vs market1Y

What the scans say today

6 of 47 matched on 10 Sep
JLHL matches 6 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Valuation against its own history

500 sessions since 26 September 2024
median 10×
11×
now 10×
JLHL trades at 10× trailing earnings, close to its median of 10× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.

Recent filings

from the exchange, newest first
08-07
13:44
Analyst call
1 day+0.35 days-0.220 days-7.5
Analyst call filings were typically +0.11pt vs the market over the next 5 sessions (n=4,339)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
24326327329028732332141122.2%9.1%Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • revenue grew 43% against the same quarter a year earlier

Going against it

  • profit dropped 16% year on year
  • net margin narrowed from 16.4% to 9.1%
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
30 Jun · consolidated
41151385.729.1%
Q3 FY25
31 Dec · consolidated
32167538.0116.4%
Q2 FY25
30 Sep · consolidated
32369527.8616.0%
Q1 FY25
30 Jun · consolidated
28760456.8015.5%
Q4 FY24
31 Mar · consolidated
29062456.4915.6%
Q3 FY24
31 Dec · consolidated
27358446.5616.0%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-8.4%
Versus 200-day average+2.9%
Below 52-week high-15.5%
Above 52-week low+17.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)22.1
Higher closes in last 50 of 5
Six-month return+9.59%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.66%
Volume versus 20-day0.2x
Median daily turnoverRs 3.0 cr

Peers

Healthcare · 68 classified companies
JLHL trades at 9.9× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — cheaper than them, by 78%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA446,51037.5−4.27%+13.20%260.5
DIVISLAB250,12085.5+9.75%+54.92%372.1
TORNTPHARM166,86180.7+0.76%+34.85%128.2
APOLLOHOSP127,98258.9+3.52%+15.00%261.1
ZYDUSLIFE111,55625.5−7.24%+7.93%133.6
CIPLA110,94233.1−6.13%−10.95%108.3
LAURUSLABS105,07996.4+5.14%+115.20%353.0
MAXHEALTH101,08169.4+3.09%−11.35%184.0
AUROPHARMA96,00025.9+0.08%+49.31%122.2
DRREDDY95,44030.0−4.75%−12.17%122.9
LUPIN95,00717.1−8.91%+3.66%155.0
JLHL1,8429.9−8.24%−4.94%3.0
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet

Recent sessions

what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
SessionScansWhich
9 Sep1Oversold, but trend intact
8 Sep3Back above the 200-day line, Uptrend taking a breather, Oversold, but trend intact